SEGMENT INFORMATION (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2025 USD ($) segment	Jun. 30, 2024 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment			1
Number of reportable segments | segment			1
Segment Reporting Information [Line Items]
Total revenues	$ 69	$ 198	$ 271	$ 296
Operating expenses
Research and development	4,881	7,306	11,004	11,014
General and administrative	2,730	3,288	6,005	7,058
Operating loss	(7,542)	(10,396)	(16,738)	(17,776)
Income tax expense	0	0	0	0
Loss from continuing operations	(5,747)	(9,395)	(14,350)	(15,636)
Net loss	(5,755)	(9,406)	(14,366)	(15,655)
Reportable Segment
Operating expenses
Other segment items	750	882	1,779	1,687
General and administrative	2,730	3,288	6,005	7,058
Total operating expenses	7,611	10,594	17,009	18,072
Operating loss	(7,542)	(10,396)	(16,738)	(17,776)
Other income, net	1,795	1,001	2,388	2,140
Loss from continuing operations before income taxes	(5,747)	(9,395)	(14,350)	(15,636)
Income tax expense	0	0	0	0
Loss from continuing operations	(5,747)	(9,395)	(14,350)	(15,636)
Loss from discontinued operations, net of income taxes	(8)	(11)	(16)	(19)
Net loss	(5,755)	(9,406)	(14,366)	(15,655)
Royalty revenues | Reportable Segment
Segment Reporting Information [Line Items]
Total revenues	69	198	271	296
Repibresib (VYN201) | Reportable Segment
Operating expenses
Research and development	2,464	4,529	5,041	6,426
VYN202 | Reportable Segment
Operating expenses
Research and development	$ 1,667	$ 1,895	$ 4,184	$ 2,901